Tzu Chi Medical Journal
Volume 21, Issue 1 , Pages 18-27 , March 2009

The Current Status of Coronary Drug-Eluting Stents

  • Chih-Wei Chen

      Affiliations

    • Division of Cardiology, Department of Internal Medicine, Buddhist Dalin Tzu Chi General Hospital, Chiayi, Taiwan
    • Division of Cardiology, Department of Internal Medicine, College of Medicine, Tzu Chi University, Hualien, Taiwan
    • ,
  • Chin-Lon Lin

      Affiliations

    • Division of Cardiology, Department of Internal Medicine, Buddhist Dalin Tzu Chi General Hospital, Chiayi, Taiwan
    • Division of Cardiology, Department of Internal Medicine, College of Medicine, Tzu Chi University, Hualien, Taiwan
    • Corresponding Author InformationCorresponding author. Division of Cardiology, Department of Internal Medicine, Buddhist Dalin Tzu Chi General Hospital, 2, Min-Sheng Road, Dalin, Chiayi, Taiwan

Received 11 August 2008 ,Revised 15 September 2008 ,Accepted 9 October 2008.

References 

  1. Gruentzig AR , King SB , Schlumpf M , Siegenthaler W . Long-term follow-up after percutaneous transluminal coronary angioplasty: the early Zurich experience . N Engl J Med . 1987;316:1127–1132
  2. Gauters C , Isner JM . The biology of restenosis . In:  Topol EJ editors. Textbook of Cardiovascular Medicine . Philadelphia: Lippinocott-Raven; 1998;p. 2465–2490
  3. Holmes DR , Vliestra RE , Smith HC , et al.   Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute . Am J Cardiol . 1984;53:77–81
  4. Fischman DL , Leon MB , Baim DS , et al.   A randomized comparison of coronary-stent placement and balloon angio-plasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators . N Engl J Med . 1994;331:496–501
  5. Serruys PW , de Jaegere P , Kiemeneij F , et al.   A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group . N Engl J Med . 1994;331:489–495
  6. Bhargava B , Karthikeyan G , Abizaid AS , Mehran R . New approaches to preventing restenosis . BMJ . 2003;327:274–279
  7. Moss JW , Lon MB , Popma JJ , et al.   Sirolimus-elutings versus standard stents in patients with stenosis in a native coronary artery . N Engl J Med . 2003;349:1315–1323
  8. Park SJ , Shim WH , Ho DS , et al.   A paclitaxel-eluting stent for the prevention of coronary restenosis . N Engl J Med . 2003;348:1537–1545
  9. Stone GW , Ellis SG , Cox DA , et al.   One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial . Circulation . 2004;109:1942–1947
  10. Nikol S , Huehns TY , Hofling B . Molecular biology and post-angioplasty restenosis . Atherosclerosis . 1996;123:17–31
  11. Rajagopal V , Rockson SG . Coronary restenosis: a review of mechanisms and management . Am J Med . 2003;115:547–553
  12. Casscells W , Engler D , Willerson JT . Mechanisms of reste-nosis . Tex Heart Inst J . 1994;21:68–77
  13. Pakala R , Willerson JT , Benedict CR . Effect of serotonin, thromboxane A2, and specific receptor antagonists on vascular smooth muscle cell proliferation . Circulation . 1997;96:2280–2286
  14. Farb A , Weber DK , Kolodgie FD , Burke AP , Virmani R . Morphological predictors of restenosis after coronary stenting in humans . Circulation . 2002;105:2974–2980
  15. Sollott SJ , Cheng L , Pauly RR , et al.   Taxol inhibits neointi-mal smooth muscle cell accumulation after angioplasty in the rat . J Clin Invest . 1995;95:1869–1876
  16. Meredith IT , Ormiston J , Whitbourn R , et al.   First-in-human study of the Endeavor ABT-578-eluting phosphorylcholine-encapsulated stent system in de novo native coronary artery lesions: Endeavor I Trial . Euro Intervention . 2005;1:157–164
  17. Serruys PW , Ruygrok P , Neuzner J , et al.   A randomised comparison of a durable polymer everolimus-eluting stent with a bare metal coronary stent . Euro Intervention . 2005;1:58–65
  18. Marx SO , Mark AR . Bench to bedside: the development of rapamycin and its application to stent stenosis . Circulation . 2001;104:853–858
  19. Burke SE , Lubbers NL , Chen YW , et al.   Neointimal formation after balloon-induced vascular injury in Yucaran minipigs is reduced by oral rapamycin . J Cardiovasc Pharmacol . 1999;33:829–835
  20. Gallo R , Padurean A , Jayaraman T , et al.   Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle . Circulation . 1999;99:2164–2170
  21. Sousa JE , Costa MA , Abizaid A , et al.   Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angi-ography and three-dimensional intravascular ultrasound study . Circulation . 2001;103:192–195
  22. Morice MC , Serruys PW , Sousa JE , et al.   A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization . N Engl J Med . 2002;346:1773–1780
  23. Fajadet J , Morice MC , Bode C , et al.   Maintenance of long-term clinical benefit with sirolimus-eluting coronary stents: three-year results of the RAVEL trial . Circulation . 2005;111:1040–1044
  24. Moses JW , Leon MB , Popma JJ , et al.   Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery . N Engl J Med . 2003;349:1315–1323
  25. Weisz G , Leon MB , Holmes DR , et al.   Two-year outcomes after sirolimus-eluting stent implantation: results from the sirolimus-Eluting Stent in de Novo Native Coronary Lesions (SIRIUS) trial . J Am Coll Cardiol . 2006;47:1350–1355
  26. Schofer J , Schluter M , Gershlick AH , et al.   Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blinded, randomised controlled trial (E-SIRIUS) . Lancet . 2003;362:1093–1099
  27. Schampaert E , Cohen EA , Schluter M , et al.   The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS) . J Am Coll Cardiol . 2004;43:1110–1115
  28. Schampaert E , Moses JW , Schofer J , et al.   Sirolimus-eluting stents at two years: a pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularization and stent thrombosis . Am J Cardiol . 2006;98:36–41
  29. Kelbaek H , Thuesen L , Helqvist S , et al.   The Stenting Coronary Arteries in Non-stress/benestent Disease (SCANDSTENT) trial . J Am Coll Cardiol . 2006;47:449–455
  30. Kelbaek H , Klovgaard L , Helqvist S , et al.   Long-term outcome in patients treated with sirolimus-eluting stents in complex coronary artery lesions: 3-year results of the SCANDSTENT (Stenting Coronary Arteries in Non-Stress/Benestent Disease) trial . J Am Coll Cardiol . 2008;51:2011–2016
  31. Grube E , Silber S , Hauptmann KE , et al.   TAXUS I: six- and twelve-month results from a randomized, double-blind trial on a slow-release paclitaxel-eluting stent for de novo coronary lesions . Circulation . 2003;107:38–42
  32. Colombo A , Drzewiecki J , Banning A , et al.   Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions . Circulation . 2003;108:788–794
  33. Stone GW , Ellis SG , Cox DA , et al.   One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS IV trial . Circulation . 2004;109:1942–1947
  34. Stone GW , Ellis SG , Cannon L , et al.   Comparison of a polymer-based paclitaxel-eluting stent with a bare-metal stent in patients with complex coronary artery disease: a randomized control trial . JAMA . 2005;294:1215–1223
  35. Dawkins KD , Grube E , Guagliumi G , et al.   Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice . Circulation . 2005;112:3306–3313
  36. Meredith IT , Ormiston J , Whitbourn R , et al.   Four-year clinical follow-up after implantation of the endeavor zotarolimus-eluting stent: ENDEAVOR I, the first-in-human study . Am J Cardiol . 2007;100:56–61
  37. Fajadet J , Wijns W , Laarman GJ , et al.   Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial . Circulation . 2006;114:798–806
  38. Goy JJ , Stauffer JC , Siegenthaler M , Benoit A , Seydoux C . A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of interventional cardiology: the TAXi trial . J Am Coll Cardiol . 2005;45:308–311
  39. Windecker S , Remondino A , Eberli FR , et al.   Sirolimus-eluting and paclitaxel-eluting stents for coronary revascu-larization . N Engl J Med . 2005;353:653–662
  40. Morice MC , Colombo A , Meier B , et al.   Sirolimus-vs paclitaxel-eluting stents in de novo coronary artery lesions: the REALITY trial: a randomized controlled trial . JAMA . 2006;295:895–904
  41. Galloe AM , Thuesen L , Kelbaek H , et al.   For the SORT OUT II investigators. Comparison of paclitaxel- and sirolimus-eluting stents in everyday clinical practice: the SOPT OUT II randomized trial . JAMA . 2008;299:409–416
  42. Kastrati A , Dibra A , Eberle S , et al.   Sirolimus-eluting stents vs paclitaxel-eluting stents in patients with coronary artery disease: meta-analysis of randomized trials . JAMA . 2005;294:819–825
  43. Schomig A , Dibra A , Winkecker S , et al.   A meta-analysis of 16 randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in patients with coronary artery disease . J Am Coll Cardiol . 2007;50:1373–1380
  44. Dibra A , Kastrati A , Mehilli J , et al.   Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients . N Engl J Med . 2005;353:663–670
  45. Kim YH , Park SW , Lee SW , et al.   Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease . Circulation . 2006;114:2148–2153
  46. Mehilli J , Dibra A , Kastrati A , Pache J , Dirschinger J , Schomig A . Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels . Eur Heart J . 2006;27:260–266
  47. Kandzari DE , Leon MB , Popma JJ , et al.   Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial . J Am Coll Cardiol . 2006;48:2440–2447
  48. Kandzari DE , Leon MB . Overview of pharmacology and clinical trials program with the zotarolimus-eluting endeavor stent . J Interv Cardiol . 2006;19:405–413
  49. Serruys PW , Ruygrok P , Neuzner J , et al.   A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial . Euro Intervention . 2006;2:286–294
  50. Stone GW , Midei M , Newman W , et al.   Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease . JAMA . 2008;229:1903–1913
  51. Marzocchi A , Saia F , Piovaccari G , et al.   Long-term safety and efficacy of drug-eluting stents: two-year results of the REAL (REgistro AngiopLastiche dell'Emilia Romagna) mul-ticenter registry . Circulation . 2007;115:3181–3188
  52. Spaulding C , Daemen J , Boersma E , Cutlip DE , Surruys PW . A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents . N Engl J Med . 2007;356:989–997
  53. Cutlip DE , Windecker S , Mehran R , et al.   Clinical end points in coronary stent trials: a case for standardized definitions . Circulation . 2007;115:2344–2351
  54. Lagerqvist B , James SK , Stenestrand U , et al.   Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden . N Engl J Med . 2007;356:1009–1019
  55. Kuchulakanti PK , Chu WW , Torguson R , et al.   Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents . Circulation . 2006;113:1108–1113
  56. Stone GW , Ellis SG , Colombo A , et al.   Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation . Circulation . 2007;115:2842–2847
  57. Mauri L , Hsieh WH , Massaro JM , et al.   Stent thrombosis in randomized clinical trials of drug-eluting stents . N Engl J Med . 2007;356:1020–1029
  58. Stone GW , Moses JW , Ellis SG , et al.   Safety and efficacy of sirolimus- and paclitaxel-eluting stents . N Engl J Med . 2007;356:998–1008
  59. Daemen J , Tanimoto S , Garcia-Garcia HM , et al.   Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries) . Am J Cardiol . 2007;99:1027–1032
  60. Daemen J , Wenasester P , Tsuchida K , et al.   Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study . Lancet . 2007;369:667–678
  61. Iakovou I , Schmidt T , Bonizzoni E , et al.   Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents . JAMA . 2005;293:2126–2130
  62. Finn AV , Kolodgie FD , Harnek J , et al.   Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclit axel-eluting stents . Circulation . 2005;112:270–278
  63. Hofma SH , van der Giessen WJ , van Dalen BM , et al.   Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation . Eur Heart J . 2006;27:166–170
  64. Kotani J , Awata M , Nanto S , et al.   Incomplete neointimal coverage of sirolimus-eluting stents: angioscopic findings . J Am Coll Cardiol . 2006;47:2108–2111
  65. Joner M , Finn AV , Farb A , et al.   Pathology of drug-eluting stents in human: delayed healing and late thrombotic risk . J Am Coll Cardiol . 2006;48:193–202
  66. Airoldi F , Colombo A , Morici N , et al.   Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment . Circulation . 2007;116:745–754
  67. Park DW , Park SW , Park KH , et al.   Frequency of and risk factors for stent thrombosis after drug-eluting stent implantation during long-term follow-up . Am J Cardiol . 2006;98:352–356
  68. Pfisterer M , Brunner-La Rocca HP , Buser PT , et al.   Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observation study of drug-eluting stent versus bare-metal stents . J Am Coll Cardiol . 2006;48:2584–2591
  69. Spertus JA , Kettelkamp R , Vance C , et al.   Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drug-eluting stent placement: results from the PREMIER registry . Circulation . 2006;113:2803–2809
  70. King SB , Smith SC , Hirshfeld JW , et al.   2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guideline: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee . Circulation . 2008;117:261–295

PII: S1016-3190(09)60004-5

doi: 10.1016/S1016-3190(09)60004-5

Tzu Chi Medical Journal
Volume 21, Issue 1 , Pages 18-27 , March 2009

Article Tools